Stockwinners Market Radar for May 23, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:42 EDT GreenSky CEO says recent volatility created opportunity to accelerate buybacks - CEO David Zalik says: "With greater than $4.5B of unused bank commitments available to fund GreenSky (GSKY) transaction growth well into 2020, our disclosure that, for its own strategic reasons, we do not expect Regions Financial (RF), to renew its existing commitment with GreenSky upon expiration of its term, is hardly noteworthy. While we anticipate periodically announcing both new bank partner funding commitments along with the expansion of existing bank funding commitments in the ordinary course of business, given our year plus of funding headroom, we feel no sense of urgency to add new bank partners to our GreenSky funding consortium... The recent volatility in GreenSky's share price since the filing of the 10-Q has created an attractive opportunity for the company to accelerate its share repurchases, consistent with our Board approved share repurchase program, for the benefit of all long-term GreenSky shareholders. We have repurchased over $100M thus far, and intend to continue to buy back our shares aggressively."

18:57 EDT TG Therapeutics CEO: We're a bit of an unconventional company - In an interview on CNBC's Mad Money, TG Therapeutics CEO Michael Weiss said: We've had a string of nice results... In MS, we have a great value proposition... We can be very competitive on price since we're a small company... We are targeting large markets.

18:32 EDT EP Energy suspends NYSE trading, begins trading on OTC markets - EP Energy confirmed that the NYSE has suspended trading in the company's common stock, effective immediately, and has initiated proceeding to delist the common stock from the NYSE. The determination was based on "abnormally low" price levels of the company's common stock. The company expects that its common stock will begin to trade on OTC Pink markets beginning May 24 under the symbol "EPEG". The transition to the over-the-counter markets will not affect the company's business operations. The company will remain subject to the public reporting requirements of the SEC following the transfer.

18:06 EDT Hope Bancorp names Kevin S. Kim chairman of the board - Hope Bancorp, Inc. announced that its board of directors appointed President and Chief Executive Officer Kevin S. Kim as chairman of the board of directors of the company and bank, effective immediately. Kim succeeds Scott Yoon-Suk Whang, who was appointed Lead Independent Director of the company and Bank, effective immediately. "Our Board of Directors has absolute confidence in Mr. Kim's ability to lead the Company's strategic vision," said Scott Yoon-Suk Whang, Lead Independent Director. "We believe that unifying the role of the Chairman and CEO is the most effective leadership structure at this time. And in accordance with our governance philosophy, I will continue my active participation as the Lead Independent Director on behalf of the Board and provide appropriate independent oversight. We also believe this structure will further promote our Board's effectiveness and more appropriately allocate authority and responsibility between the Board and management."

18:00 EDT Extra Space Storage raises quarterly dividend by 4.7% to 90c per share - The dividend is payable on June 28, 2019 to stockholders of record at the close of business on June 14, 2019.

17:57 EDT HP Inc CFO sees FY19 tax rate of about 19% - Says FY19 EPS outlook of $2.14-$2.21 was updated from $2.12-$2.22 prior forecast.

17:48 EDT Technical Comm Corp receives compliance and plan acceptance notices from Nasdaq - Technical Communications Corporation Reports Nasdaq Notice of Continued Noncompliance and Acceptance Technical Communications Corporation has been notified by the Nasdaq Listing Qualifications that it was not in compliance with listing rules due to the company's failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, as well as its continued failure to file its Annual Report on Form 10-K for the fiscal year ended September 29, 2018 and Quarterly Report on Form 10-Q for the quarter ended December 29, 2018. Completion of the annual and quarterly reports has been impacted by the company's review of its revenue recognition policy, which revealed errors in the company's recognition of revenue for certain contracts resulting from a misinterpretation of accounting standards related to revenue recognition. TCC also expects to file restatements of the financial statements included in certain previously-filed periodic reports. Nasdaq also notified TCC that it had accepted the company's modified plan to regain compliance with such rule, which permits the continued listing of the company's common stock on the Nasdaq Capital Market. Nasdaq granted the company an extension until no later than July 15 to file its Annual Report on Form 10-K for the fiscal year ended September 29, 2018 together with its Quarterly Reports on Form 10-Q for the quarters ended December 29, 2018 and March 31, 2019, and any restatements to previously-filed periodic reports of the company impacted by the company's review of its revenue recognition policy.

17:38 EDT Rosetta Stone officer Sonia Galindo sells over $107K in company shares - Rosetta Stone officer Sonia Galindo disclosed in a filing that she had sold 4,496 shares of company shares at an average price of $23.91 on May 22. The total transaction value of the sale was $107,499.

17:15 EDT Raytheon awarded $355.49M Navy contract for AGM-88B missiles - Raytheon has been awarded a $355.49M firm-fixed-price, indefinite-delivery/indefinite-quantity contract for AGM-88B high speed anti-radiation missiles, or HARM/replacement exchange in-kind, or REIK, for HARM control section modification. This contract provides for the refurbishment of live AGM-88Bs and conversion of AGM-88B into Ccptive air training missiles for approved foreign military sales countries. Work will be performed in Tuscon, Arizona and is expected to be complete by 2027. This contract involves foreign military sales to Qatar, Taiwan and Bahrain. Additional countries may be added after contract award. This award is the result of a sole-source acquisition. FY19 foreign military sales funds in the amount of $76.07M is being obligated on a delivery order at the time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:06 EDT MYnd Analytics director John Pappajohn purchases 200K shares of company stock - MYnd Analytics director John Pappajohn disclosed in a filing that he had purchased 200,000 shares of company stock at an average price of $1.25 per share for a total transaction value of $250,800.

16:56 EDT Integrated Core Strategies reports 5.7% passive stake in MacroGenics - Integrated Core Strategies disclosed a 5.7% stake in MacroGenics, which represents over 2.8M shares. The filing does not allow for activism.

16:47 EDT Dynavax to restructure to focus on vaccine business - Dynavax Technologies Corporation announced a strategic restructuring to prioritize its vaccine business by focusing on the company's first commercial product HEPLISAV-B. As part of the restructuring, the company will explore strategic alternatives for its immuno-oncology portfolio and will reduce the company's workforce and operations to focus resources on HEPLISAV-B commercialization. While the company's near-term focus will be on HEPLISAV-B sales execution, the company is assessing additional opportunities to leverage its 1018 adjuvant, as well as evaluating other opportunities for growth. In addition, CEO Eddie Gray announced that he will retire from his positions as chief executive and director as of August 1, 2019. The board will conduct a search for the company's next CEO and will consider both internal and external candidates. In connection with the decision to focus on the vaccine business the company is eliminating approximately 82 current positions, representing approximately 37% of its current U.S. workforce. The company is providing severance, continuation of employee benefits and outplacement assistance to the employees affected by the restructuring. The positions eliminated are primarily related to research and clinical development for the immuno-oncology programs and general and administrative functions. Restructuring costs and retirement costs related to compensation and benefit expenses as well as severance costs, are expected to be approximately $5.5M, exclusive of stock compensation. The company may incur additional restructuring expenses including retirement of fixed assets and facility-related costs. The workforce reduction is expected to reduce compensation and benefits cost by approximately $16M dollars annually. After all existing oncology trials and commitments are complete, the company estimates its operating expenditures related to external oncology costs will be reduced by approximately $8M per quarter as compared to the first quarter ended March 31, 2019. The company will be responsible for certain wind-down costs and committed contractual costs for the immuno-oncology programs, including the I-SPY trial that will run through the second quarter of next year.

16:42 EDT Dynavax trading halted, news pending

16:36 EDT GWG Holdings receives noncompliance notification from Nasdaq - GWG Holdings announced that it received a letter from the Listing Qualifications Department of Nasdaq informing the company that it was not in compliance with the filing requirements for continued listing under Nasdaq Listing Rule 5250. The Nasdaq notice has no immediate effect on the listing or trading of the company's common stock on Nasdaq. As previously reported, the company received a similar letter from Nasdaq stating the company was not in compliance with the filing requirements for continued listing under Nasdaq Listing Rule 5250 as a result of the company being unable to timely file its annual report on Form 10-K for the fiscal year ended 2018. The company's inability to timely file its Form 10-K was due, in part, to a delay in finalizing the accounting for certain assets and liabilities exchanged pursuant to the amended and restated master exchange agreement, dated January 18, 2018, as amended, between the company and Beneficient, among others, which exchange was completed on December 28, 2018. For the same reasons, as of May 15, the company was unable to timely file its quarterly report on Form 10-Q for the fiscal quarter ending March 31. As a result, the company received the letter from Nasdaq stating the company is not in compliance with the filing requirements for continued listing under Nasdaq Listing Rule 5250. The company has until June 17 to submit a plan to regain compliance with Nasdaq's filing requirements for continued listing. If the company submits an acceptable compliance plan, Nasdaq is permitted to grant an extension of up to 180 days from the Form 10-K's filing due date for the company to regain compliance with Nasdaq's filing requirements for continued listing. The company anticipates that it will regain compliance with the Nasdaq continued listing requirements upon filing its Form 10-K for fiscal year ended 2018 and Form 10-Q for the fiscal quarter ending March 31. If the company is unable to regain compliance prior to June 17, it expects to do so within the Nasdaq extension period.

16:32 EDT Mosaic doubles quarterly dividend to 5c per share - The dividend will be paid on June 20, 2019, to stockholders of record as of the close of business on June 6, 2019.

16:31 EDT Therapix Biosciences receives Nasdaq noncompliance notification - Therapix Biosciences Ltd. announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Capital Market notifying the company that Nasdaq has determined that Therapix's stockholders' equity does not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550b1. The Nasdaq notification does not affect the listing of the company's American Depositary Shares at this time.

16:27 EDT Calix director Kevin Denuccio purchases over $221K in company shares - Calix director Kevin Denuccio disclosed in a filing that he had purchased 33,500 shares of company stock at an average price of $6.62 per share on May 22. The total transaction value of the purchase was $221,807.

16:20 EDT DXC Technology raises quarterly dividend to 21c from 19c per share - The dividend will be paid on July 16, 2019 to stockholders of record at the close of business on June 5, 2019.

16:19 EDT Globus Medical announces results of ExcelsiusGPS clinical study published - Globus Medical announced the results of a clinical study that evaluated the ExcelsiusGPS robotic navigation system compared to traditional pedicle screw placement techniques. Published in the Journal of Robotic Surgery, the study demonstrated a 99% screw placement success rate with no malpositions or postoperative returns to the O.R. related to screw placement. The study explored how the ExcelsiusGPS navigated robotic technology combines the ability to use three imaging workflows with navigation and guidance to place pedicle screws with real-time feedback. A total of 562 lumbar pedicle screws were placed across six vertebral levels during 55 single-position lateral, 16 anterior and 29 posterior interbody fusion cases. Interbody placement was performed manually.

16:17 EDT DowDuPont stockholders approve reverse stock split, board determines ratio - DowDuPont announced that its stockholders approved a reverse stock split of the company's common stock. Stockholders voted approximately 97% in favor of the reverse stock split. Stockholders approved the reverse stock split at a ratio of not less than 2-for-5 and not greater than 1-for-3, with an exact ratio as may be determined by the board. DowDuPont also announced that after receiving stockholder approval in favor of the reverse stock split, its board established a reverse stock split ratio of one new share of DowDuPont common stock for three shares of current DowDuPont common stock. The reverse stock split is expected to occur on June 1. The reverse stock split is intended to increase the market price of DowDuPont's common stock in connection with the company's intended distribution of all of the shares of common stock of its wholly owned subsidiary, Corteva, which holds the company's Agriculture Business, to the holders of the company's common stock on a pro rata basis.

16:14 EDT Autodesk down 6% to $159.44 after Q1 results miss estimates - The company's Q2 guidance, at the midpoint, also missed estimates.

16:13 EDT Freeport McMoRan to sell part of cobalt business for about $150M - Freeport-McMoRan announced an agreement to sell its cobalt refinery in Kokkola, Finland and related cobalt cathode precursor business to Umicore for total consideration of approximately $150M, plus working capital at the time of close. Under the terms of the agreement, FCX will separate its cobalt business prior to completing the transaction. Umicore will acquire the refinery and cathode precursor business, which represents approximately 60% of the refinery's historical revenues. FCX and its partners will retain Freeport Cobalt's remaining cobalt business with operations in Kokkola, Finland and with sales offices in the U.S., Europe and Asia. The retained cobalt business is a leading global producer of cobalt fine powders, chemicals, catalyst, ceramics and pigments.

16:11 EDT HP Inc. higher by 1.6% after reporting Q2 results, giving Q3, FY19 guidance

16:10 EDT Duke Energy appoints Bonnie Titone as Chief Information Officer - Duke Energy has appointed Bonnie Titone as Chief Information Officer, effective June 19. Titone was most recently VP of information business technology at Pacific Gas and Electric. Prior to her work at PG&E, Titone served in leadership roles at Volkswagen and Toyota.

16:09 EDT Novocure says FDA approves NovoTTF-100LTM system in combo with pemetrexed - Novocure announced that the U.S. Food and Drug Administration has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma. NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating Fields to the region of the tumor. Tumor Treating Fields therapy uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

16:04 EDT Autodesk reports Q1 total ARR up 33% to $2.83B

16:03 EDT Autodesk sees FY20 free cash flow ~ $1.35B

16:02 EDT TDH Holdings receives Nasdaq continued listing deficiency notice - TDH Holdings received a notification letter from Nasdaq Listing Qualifications advising the company that it failed to maintain a minimum of $2.5M in stockholders' equity for continued listing on the Nasdaq Stock Market. The company's recently filed Form 20-F for the period ended December 31, 2018 reported stockholders' equity of $(1,936,567). Since the company does not meet the alternatives of market value of listed securities or net income from continuing operations, it no longer complies with the Nasdaq Listing Rules. As a result, the company has 45 calendar days, or no later than July 5, to submit a plan to regain compliance with the foregoing listing requirement. To the extent the company's plan of compliance is accepted, it may be granted an extension of up to 180 calendar days from the date of the deficiency notification to evidence compliance. In the event the company's plan is not accepted, the company's securities may be subject to delisting and the company may have the opportunity to appeal the staff's delisting determination to a Hearings Panel.

15:41 EDT Addiction Labs of America developing cannabis, CBD pharmacogenetics test - Addiction Labs of America, the laboratory division of American Addiction Centers, announced that it is in the early stages of developing a pharmacogenetics test for cannabis and other cannabis products, such as cannabidiol, or CBD. "It's critical that we know how different people, based on their genetic makeup, process or metabolize cannabis or CBD, and that's information pharmacogenetic testing could tell us. Right now, it's a guessing game of trial and error. While there are many people who benefit both medicinally and recreationally from cannabis products, we also know there is a subset of the population who can become addicted to cannabis and experience psychiatric symptoms, such as paranoia and schizophrenia-like behavior," said Dr. Mark Calarco, Addiction Labs of America CEO. Following the announcement, AAC Holdings shares are up 22c to $1.37.

15:14 EDT DTE Energy officer Mark Stiers sells almost $1.3M in company shares - DTE Energy officer Mark Stiers disclosed in a filing that he had sold 10,000 shares of company stock at $127.84 per share on May 21. The total transaction value of the sale was $1,278,400.

15:02 EDT Pennsylvania PUC approves application related to proposed Sprint/T-Mobile merger - The Pennsylvania Public Utility Commission, or PUC, approved an application from Sprint Communications (S), seeking approval of a merger transaction that will result in Sprint's indirect transfer of control to T-Mobile USA (TMUS). Following discussion over differing proposals to address the impacts of the merger in Pennsylvania, the Commission voted 3-2 in support of a motion offered by Commissioner Andrew G. Place to approve the application, the PUC said. The approval specifically references voluntary commitments offered by Sprint involving statewide deployment of 5G wireless facilities and services in Pennsylvania. These will be implemented by New T-Mobile, a wireless carrier, and will increase the availability of broadband access in rural areas of Pennsylvania in all of its 67 counties, the PUC stated in its announcement.

14:55 EDT Chipotle disagrees with downgrade, sees no major impact from African swine fever - After BMO Capital analyst Andrew Strelzik downgraded Chipotle to Underperform, citing concerns about the impact of the Chinese outbreak of African swine fever on pork prices, a spokesperson for the company told The Fly that the "analysis is not accurate." "The cost of our pork represents less than 2% of Chipotle's total food costs. Since we purchase higher quality, more expensive pork than commodity pork, and we have pricing agreements in place, we don't expect a significant impact on our cost," Stefani Green, Manager of External Communications, said. In afternoon trading, shares of Chipotle have dropped almost 5.5% to $667.41.

14:35 EDT Huntington Ingalls VP William Ermatinger sells almost $400K in company shares - Huntington Ingalls VP William Ermatinger disclosed in a filing that he had sold 1,863 shares of company stock at an average price of $211.55 per share on May 21. The total transaction value of the sale was $394,120.

14:27 EDT NASA confirms contract with maxim $375M value awarded to Maxar Technologies - NASA announced the selection of Maxar Technologies, formerly SSL, in Westminster, Colorado, to develop and demonstrate power, propulsion and communications capabilities for NASA's lunar Gateway. This firm-fixed price award includes an indefinite-delivery/indefinite-quantity portion and carries a maximum total value of $375M. The contract begins with a 12-month base period of performance and is followed by a 26-month option, a 14-month option and two 12-month options. "The power and propulsion element is the foundation of Gateway and a fine example of how partnerships with U.S. companies can help expedite NASA's return to the Moon with the first woman and next man by 2024. It will be the key component upon which we will build our lunar Gateway outpost, the cornerstone of NASA's sustainable and reusable Artemis exploration architecture on and around the Moon," said NASA Administrator Jim Bridenstine.

14:06 EDT Maxar Technologies up 17% after selection for NASA project - Maxar Technologies shares are up 16.7% to $8.09 in afternoon trading following reports that the company was selected by NASA to develop and build the first segment of its Gateway outpost, which is part of the agency's plan to send astronauts to the moon's surface in 2024.

13:11 EDT Verint says short seller report 'inaccurate and deliberately misleading' - Verint Systems issued a statement in response to a presentation released by short selling hedge fund, Spruce Point Capital Management, LLC: "The self-serving short seller report disseminated today is inaccurate and deliberately misleading, and is intended to destroy shareholder value. Verint is a market leader with strong business momentum driven by the successful execution of our customer-focused strategy, which is delivering an expanding portfolio, growing customer base, and strong financial performance. We stand by all of our public disclosure, including the recently provided long-term organic growth targets for revenue and margin expansion. We will let our performance speak for itself, and we look forward to discussing our strong momentum, results and outlook on our first quarter earnings call, which is scheduled for Wednesday, May 29th at 4:30 pm ET. To receive accurate information about our Company, we encourage all investors to review materials filed by Verint with the SEC and available on our investor relations website."

13:02 EDT Wellesley Bancorp raises quarterly cash dividend 9.1% to 6c per share - Wellesley Bancorp announced that on May 22, 2019, its Board of Directors approved a quarterly cash dividend to its stockholders 6c per common share, an increase of 9.1% from the prior quarter's dividend, to be paid on June 19, 2019 to stockholders of record as of the close of business on June 5, 2019.

12:44 EDT Becton Dickinson VP Samrat Khichi sells almost $3.8M in company stock - Becton Dickinson VP Samrat Khichi disclosed in a filing that he had sold 16,085 shares of company stock at $234.68 per share on May 21. The total transaction value of the sale was $3,774,828.

12:34 EDT Tesla has no immediate plans to raise money, Charles Gasparino tweets - Charles Gasparino of Fox Business said via Twitter: "Bankers dealing w @Tesla say co has no immediate plans to raise money despite biz woes; bankers say $TSLA may TRY TO raise money if biz continues to deteriorate; key date: second-quarter deliveries in July." Reference Link

12:03 EDT Facebook removed 2.2B fake accounts in Q1 of 2019

12:00 EDT Advanced Drainage rises 8.6% - Advanced Drainage is up 8.6%, or $2.37 to $29.81.

12:00 EDT Universal Corporation rises 13.0% - Universal Corporation is up 13.0%, or $6.75 to $58.50.

11:19 EDT T2 Biosystems highlights clinical data at ECCMID, MAD-ID meetings - T2 Biosystems highlighted the latest clinical data and customer case studies for the T2Bacteria and T2Candida Panels that were presented at recent medical meetings. In April, case studies of patients tested with the T2Bacteria Panel and T2Resistance Panel were presented at the European Congress of Clinical Microbiology & Infectious Diseases in Amsterdam in an Integrated Symposium by Dr. Giulia De Angelis. Key highlights from the case studies: Three T2Bacteria clinical cases were reviewed showing an approximately 24 hour to 37 hour time savings over direct-from-blood-culture MALDI Biotyper and one T2Bacteria clinical case of culture-negative sepsis missed altogether by blood culture but detected by the T2Bacteria Panel. Multiple T2Carba Resistance+ clinical cases were reviewed showing an average of a 30 hour time savings with T2Carba Resistance+ over direct-from-blood-culture PCR methods. For T2Bacteria panel, Dr. De Angelis concluded: "Study and clinical cases demonstrate the ability of the T2Bacteria Panel to detect infections and poly-microbial infections faster than blood culture...Clinical case study demonstrates the ability for T2Bacteria to detect probable infections missed by blood culture." For the T2Resistance Panel, Dr. De Angelis concluded: "Case studies demonstrate the opportunity for direct-from-blood resistance gene detection to provide results faster than blood culture-based diagnostics and to impact clinical care." In addition to Dr. De Angelis' presentation during the Integrated Symposium, which was viewed by approximately 400 attendees, Professor Michael Bauer; Dr. Cornelius Clancy; and Dr. Thomas Walsh gave presentations covering additional patient case studies and providing an overview of the application and clinical results using the T2Bacteria and T2Candida Panels for a variety of patients. Key highlights from these presentations: Professor Bauer noted that "appropriate and rapid delivery of targeted antimicrobials is critical for surviving sepsis" and that rapid diagnostic tests can provide "cost savings with antimicrobial use as well as a reduction of length of stay associated costs." Dr. Clancy provided patient case studies and noted that the T2Bacteria Panel is appropriate for a variety of patients, including those in the high-risk intensive care unit and the emergency department. Dr. Walsh concluded that the T2Bacteria and T2Candida Panels could improve outcomes for immunocompromised patients by providing earlier diagnosis and more sensitive detection of blood stream pathogens, thereby reducing length of stay and improving the chance of survival. In addition, several poster presentations covering the T2Bacteria, T2Candida, and T2Resistance Panels were presented at ECCMID and the T2 Biosystems team met with potential customers at the Company's booth and provided demonstrations on the ease-of-use of the T2Dx Instrument.

11:10 EDT EQT Corporation files definitive proxy, mails letter to shareholders - EQT Corporation announced that it has filed its definitive proxy statement with the U.S. SEC in connection with the company's 2019 Annual Meeting of Shareholders, scheduled for July 10, 2019. EQT shareholders of record as of the close of business on May 14, 2019, will be entitled to vote at the Annual Meeting. The EQT Board of Directors recommends that shareholders support the EQT team by voting on the GOLD universal proxy card "FOR" EQT's 12 director nominees. In connection with the filing of the definitive proxy statement, the independent directors of EQT mailed a letter to shareholders. Highlights of the letter include: "EQT has transformed into a focused pure play upstream industry leader with a simplified corporate structure and a refreshed Board and leadership team. The new EQT team is successfully executing an ambitious, realistic strategic plan to drive substantial and sustainable free cash flow growth and value creation. EQT generated more than $300M of adjusted free cash flow in the last two quarters; and The company is on track to achieve approximately $300M-$400M of adjusted free cash flow in 2019, and at least $2.9B of adjusted free cash flow2 through 2023. EQT's independent, diverse Board slate has the right skills and experience to oversee EQT's progress. The Board values feedback from shareholders and is committed to continually enhancing governance as demonstrated by the company's three new independent director nominees and use of a universal proxy card."

11:04 EDT ProcessMap, IBM announce joint initiative to develop IoT solutions - ProcessMAP and IBM announced a joint initiative to develop IoT enabled solutions that monitor workers in hazardous environments, including those working on construction sites, manufacturing floors, and outdoor rugged environments by using IoT technologies leveraging sensors and wearables. Real-time actionable analytics based on biometric and environmental data collected from smart devices will help organizations quickly respond to safety hazards and changing environmental conditions to proactively prevent accidents from occurring.

10:45 EDT GSK to change sales representative incentive program - The company said, "We are announcing changes to our incentive programme for sales representatives in certain countries. These changes reflect the growing shift in GSK's portfolio to innovative Specialty Care products, including oncology. They will allow the company to attract and retain the best sales force talent, enhancing the quality of our dialogue with healthcare professionals and helping them better serve patients. The changes uphold our ethical and values-led approach to HCP engagement, in full compliance with laws and policies, whilst supporting delivery of strong performance. Changes will be made to our incentive programme for our Pharmaceutical and Vaccines sales representatives to better recognise and reward individual effort. Specifically in Specialty Care, the capped variable pay element of a sales representative's compensation will be evaluated on the basis of individual sales targets. These changes will be applied initially in the US, UK and Canada from July 2019 and a comprehensive training, control and monitoring framework will be put in place to ensure implementation of the new programme is fully aligned with GSK's values-based approach to HCP engagement." Reference Link

10:15 EDT Sunworks wins contract to build 1 MW solar project for California school - Sunworks announced it has been awarded an engineering, procurement and construction contract to develop a 1.0 MW solar parking canopy project for a Northern California School District. As part of the project, Sunworks will integrate an intelligent energy storage solution to help maximize clean energy generation and enhance on-site sustainability. Sunworks was contracted by ForeFront Power. Construction is expected to commence in the second half of 2019 and to be completed in the first half of 2020.

10:02 EDT Roche announces FDA 510(k) clearance for cobas TV/MG test - Roche announced U.S. FDA 510(k) clearance for the cobas TV/MG test for use on the cobas 6800/8800 Systems for the detection of Trichomonas vaginalis and/or Mycoplasma genitalium DNA in both symptomatic and asymptomatic patients. Laboratories can now simultaneously process from a single patient sample a combination of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, which provides clinicians the information they need to screen and diagnose sexually transmitted infections and improve patient care.

10:00 EDT Seadrill falls -12.9% - Seadrill is down -12.9%, or -91c to $6.12.

10:00 EDT Universal Corporation rises 8.7% - Universal Corporation is up 8.7%, or $4.51 to $56.26.

10:00 EDT Avon Products rises 13.0% - Avon Products is up 13.0%, or 46c to $3.94.

09:47 EDT Everi Holdings rises 4.5% - Everi Holdings is up 4.5%, or 50c to $11.71.

09:41 EDT Textron mentioned cautiously at Off Wall Street

09:36 EDT Blue Lion says Homestreet 'misrepresented' interactions with Dwight Capital - Blue Lion Capital, an investment firm that beneficially owns approximately 6.5% of the stock of HomeStreet, issued a statement about the "company's failure to fully engage with Dwight Capital regarding their expressed interest in acquiring HomeStreet's Fannie Mae DUS lending operations and related mortgage servicing rights." Blue Lion stated: "We were surprised and disappointed to learn yesterday from a Dwight Capital press release that HomeStreet's Chairman and CEO Mark Mason has apparently misrepresented the interactions that took place between the two firms dating back to 2017. On April 29, 2019, Dwight Capital expressed its interest in acquiring HomeStreet's Fannie Mae DUS lending operations and associated MSRs. On April 30, HomeStreet stated that it was 'not aware of Dwight Capital's interest until their press release, as they had not previously contacted us.'..Dwight Capital openly disputed HomeStreet's assertion that the Company was unaware of their interest as members of their management team had sent emails to Mark Mason in 2017 and 2018. Further, Mark Mason responded to the emails. How can the Chairman of the Board and CEO have received and sent emails and then claimed the Company knew nothing of Dwight Capital's interest? Further, when HomeStreet's press release stated it was "unaware of Dwight Capital's interest," was that the Board speaking or simply a misrepresentation to the Board by its Chairman and CEO? Blue Lion does not know the people at Dwight Capital and we do not know whether the transaction they would propose would be attractive to HomeStreet. But, we do know that when a public company makes a representation to shareholders, that representation MUST be true. It also appears that HomeStreet is not intending to substantively consider Dwight Capital's expression of interest...We continue to be astounded by what we believe to be the inability of HomeStreet's Board to perform its fiduciary duties. Blue Lion expects the Board to fully engage with Dwight Capital and communicate truthfully to shareholders the outcome of the discussions. Blue Lion has nominated two seasoned financial professionals to the Board of Directors at this year's annual meeting of HomeStreet shareholders and recommends shareholders vote the BLUE proxy card FOR the election of Charles W. Griege and Ronald K. Tanemura and FOR Blue Lion's proposal to separate the roles of Chairman and CEO. "

09:29 EDT Cinedigm acquires North American rights to 'Miss Arizona'

09:23 EDT Teekay Corp. enters agreement to extend employment of Petrojarl Banff FPSO unit - Teekay Corporation has entered into an agreement with a subsidiary of Canadian Natural Resources to extend the employment of the Petrojarl Banff FPSO unit on the Banff field in the North Sea for a period of one year to the end of August 2020 at substantially similar terms to the current contract, which includes an upside component linked to oil prices and oil/gas production.

09:19 EDT ChinaCache receives noncompliance notice from Nasdaq - ChinaCache announced that it received a notification letter from Nasdaq indicating that the company is not in compliance with Nasdaq Listing Rule 5250 because it did not timely file its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the SEC. The notification letter also contains questions relating to the company's disclosure of certain recent events, including Grant Thornton China's resignation as the company's independent auditor, the company's engagement with Michael Studer as independent auditor to the company and allegations of enterprise bribery against the company as well as Song Wang, the company's chairman and former CEO. The notification letter states that in light of the company's recent disclosure, the staff of Nasdaq has determined to apply more stringent criteria and shorten the time period for the company to submit its plan to regain compliance. The notification letter further states that the company must submit the plan and its response to the questions no later than May 31. The company is working diligently to prepare the plan and responses to the questions and confirms it will be submitting the required plan to Nasdaq within this timetable. Fuya Zheng has tendered his resignation as a director to the company's board for personal reasons. His resignation was effective as of May 21.

09:19 EDT Akoustis announces first pre-production order for tandem WiFi filter - Akoustis Technologies announced today it has received its first pre-production order from a new "Tier-1" global system-on-chip maker for Akoustis' tandem 5.2 GHz / 5.6 GHz WiFi coexistence filters for a reference design targeting tri-band WiFi customer premise equipment. Akoustis expects to ship pre-production filters to this "multibillion-dollar SoC customer" for evaluation and approval in the September quarter. This new customer is the third SoC maker to order WiFi filters for possible inclusion in a reference design, with the first two ordering 5.2 GHz filters in late 2018 and early 2019, Akoustis said in a statement. Jeff Shealy, CEO of Akoustis, stated, "We are thrilled to announce our first pre-production order for our tandem 5.2 GHz / 5.6 GHz WiFi XBAW filters from a new customer which represents our third SoC customer. Both WiFi filters leverage our patented XBAW filter process and utilize our backend supply chain." Mr. Shealy continued, "Akoustis is currently sampling its high performance 5.2 GHz and 5.6 GHz filters to multiple leading WiFi SoC and OEMs while preparing to deliver these products in high volume quantities."

09:16 EDT VirnetX signs Distribution and Service Agreement with IP Dream - VirnetX and IP Dream, a Japanese based strategic technology developer and service provider, announced that on April 18, they signed a non-exclusive Distribution and Service Agreement for IP Dream to sell VirnetX's Gabriel Collaboration Suite as well as VirnetX's Secure Domain Name technology to its clients in Japan and greater Asia.

09:12 EDT Global Ship Lease to acquire three containerships for $48.5M - Global Ship Lease has agreed to acquire three 2004-built, 7,849 TEU containerships for an aggregate purchase price of $48.5M. Upon delivery during Q2, the first vessel will commence a five-year charter with Maersk Line. The two other vessels are expected to be delivered during Q3 and will commence three-year charters with Maersk Line, with two consecutive one-year extensions at the charterer's option. The three vessels are expected to generate adjusted EBITDA of approximately $32M in aggregate for the median firm period, and a total of $47M if all options are exercised. With these additions, the company's fleet will comprise 41 vessels with a total capacity of 224,162 TEU. The company has secured new senior secured bank debt to finance a portion of the purchase price. The new debt is on market terms with a maturity of late 2024.

09:09 EDT Organovo announces need to conduct additional preclinical studies - Organovo said in last night's earnings release, "We have determined that we need to conduct additional preclinical studies, optimize our manufacturing processes, and most importantly to generate decisive scientific data regarding the prolonged functionality and therapeutic benefits of our liver tissue patch. As a result, our preclinical development will be extended into calendar 2020, and consequently we also now expect to have our pre-IND meeting with the FDA in calendar 2020, rather than the latter part of this calendar year. This change in our timeline also pushes the start of our IND-enabling studies back, with our revised plan now supporting an IND submission and the start of first-in-human trials in calendar 2021. Accordingly, we intend to devote substantially all of our financial and operating resources to meet these critical timelines. The most recent data we've generated from a much larger group of animal studies provides differing results from what we observed in our earlier pilot studies. We continue to see statistically meaningful reduction in toxic globules in the Alpha-1-antitrypsin animal models over a three-month period. However, in these and other animal models, we are also seeing evidence of shorter tissue duration than we observed in previous studies, as measured by human protein output and the quantity of hepatocytes. We'll continue to examine all aspects of our manufacturing process, with the goal of improving the durability and optimizing the functionality of our tissues."

09:04 EDT Fly Intel: Pre-market Movers - UP AFTER EARNINGS: Medtronic (MDT), up 3%... Best Buy (BBY), up 2%. ALSO HIGHER: Sprint (S), up 4% after CNBC reported Makan Delrahim, Assistant Attorney General for the Antitrust Division of the U.S. Department of Justice, has not made up his mind on the proposed merger between Sprint and T-Mobile (TMUS)... Tonix Pharmaceuticals (TNXP), up 9% after announcing that it has in-licensed a Phase 2 asset, TNX-1300, for the treatment of cocaine intoxication... S&W Seed (SANW), up 28% after the company and the agriculture division of DowDuPont (DWDP) announced they have entered into a new alfalfa agreement that terminates and replaces the December 2014 agreements between S&W and Pioneer Hi-Bred International. DOWN AFTER EARNINGS: Hormel Foods (HRL), down 5%... Weibo (WB), down 12%... Sina (SINA), down 10%... NetApp (NTAP), down 9%. LOWER: Cloudera (CLDR), down 3% after Wells Fargo analyst Philip Winslow downgraded the stock to Market Perform from Outperform saying that while CDP is still "a big deal," timing could be longer than he expected.

09:04 EDT Best Buy management says 25% tariff level will impact consumers - Best Buy management said many vendors are willing to absorb tariff costs at 10% but consumers will begin to be impacted with price increases at a 25% tariff rate.

09:00 EDT National Storage raises quarterly dividend 6.7% to 32c per share - National Storage Affiliates Trust announced its Board of Trustees declared regular cash dividends for the second quarter 2019 payable on June 28, 2019 to shareholders of record on June 14, 2019 on the following securities: a dividend of 32c per common share, representing an annualized dividend rate of $1.28. The new rate represents a 10.3% increase from the second quarter 2018 dividend rate and a 6.7% increase from the first quarter 2019 dividend rate. This increase is the eighth common share dividend increase since the company's IPO in the second quarter 2015; and a dividend of 37.5c per share on the Company's 6.000% Series A Cumulative Redeemable Preferred Shares.

08:59 EDT Revolution Lighting receives another delisting determination letter from Nasdaq - Revolution Lighting announced that the company received an additional delisting determination letter from the staff of the Listing Qualifications Department of Nasdaq, informing the company that, since the company is late in filing its quarterly report on Form 10-Q for the quarter ended March 31, Nasdaq will consider the deficiency as an additional basis for delisting the company's common stock from Nasdaq. Nasdaq Listing Rule 5250 requires listed companies to timely file all required periodic financial reports with the SEC.

08:38 EDT NewLink Genetics announces updated NLG802 results at immuno-oncology meeting - NewLink Genetics announced the NLG802 abstract was presented at the Immuno-Oncology World Congress. The Phase 1 dose-escalation study evaluated the safety, toxicity and pharmacokinetic, or PK, of NLG802 to determine the maximum tolerated dose, or MTD, or maximum biologically achievable dose, or MBAD. Data from the study was used to recommend a Phase 2 dose of NLG802. NLG802 was administered orally at five dose levels up to 1452 mg BID in 26 patients with recurrent advanced solid tumors. At the time of analysis for this presentation, five patients remain on study, 14 alive and four patients withdrew from follow-up. Six patients achieved a best response of stable disease per RECIST 1.1 criteria, with 1 patient having durable stable disease greater than nine months. No subject experienced a dose-limiting toxicity within the first 28-day cycle. The most frequently reported adverse events, or AE, regardless of attribution were fatigue, nausea, vomiting, decreased appetite and diarrhea. PK results were also reported from this study. After continuous twice-daily dosing with NLG802 at all levels, significantly higher PK exposure was observed. At 1452 mg BID, the highest dose administered, NLG802 produced a 6-fold increase in Cmax and a 4.7-fold increase in AUC compared with molar equivalent indoximod dosing. The treatment regimen was well tolerated with no NLG802-related serious adverse events, or SAE reported. MTD/MBAD had not been reached, and recommended Phase 2 dose was established at 1452 mg BID based on achieving preclinical exposure levels required for pharmacodynamic effects of indoximod. An interesting response was observed during this study involving a patient with metastatic pancreatic cancer who had failed three prior lines of therapy. NLG802 was administered to this patient as fourth line therapy and was discontinued after five weeks upon disease progression. The patient was subsequently re-challenged with gemcitabine plus nab-paclitaxel. Imaging three months after re-challenge showed a partial response, or PR, with 75% reduction in total tumor burden. In addition, the CA19-9 levels dropped 94% from levels prior to this line of therapy. No objective responses were observed after any earlier rounds of chemotherapy prior to administration of NLG802. This suggests that prior treatment with NLG802 may have contributed to the response ultimately observed in this patient.

08:33 EDT Future FinTech appoints Jing Chen as CFO - Future FinTech has appointed Jing Chen as the new CFO of the company, effective on May 21. Chen has more than 20 years of experience in accounting, financial management, and general management of several public companies. Prior to joining Future FinTech, she served as the CFO of AnZhiXinCheng Technology from August, 2018 to May, 2019. From August, 2017 to July, 2018, Chen served as CFO of Beijing Logis Technology Development Co., a company listed on The National Equities Exchange and Quotations, China's OTC market.

08:23 EDT Best Buy CEO says company achieved FY21 targets two years early

08:15 EDT USA Technologies appoints Matthew McConnell as COO - USA Technologies (USAT) announced the appointment of Matthew McConnell as COO, effective May 22, 2019. In this newly created position, McConnell will be responsible for managing USAT's day-to-day operations. McConnell will report to CEO Stephen Herbert. Most recently, McConnell held the role of SVP and general manager at Comcast NBCUniversal (CMCSK, CMCSA), where he was responsible for operating Comcast Technology Solutions, a global division of Comcast Cable.

08:14 EDT Immutep granted patent covering eftilagimod alpha by European Patent Office - Immutep announced the grant of a new patent by the European Patent Office. The new patent protects Immutep's intellectual property relating to combined therapeutic preparations comprising its active immunotherapy candidate eftilagimod alpha and a chemotherapy agent. The chemotherapy agent is either a platinum-based anti-neoplastic agent, such as oxaliplatin or carboplatin, or a topoisomerase I inhibitor, such as topotecan.

08:12 EDT ShotSpotter announces $15M stock repurchase program - ShotSpotter announced that its board has approved a program for the repurchase of up to $15M of its common stock. Repurchases, if any, under the program may be made from time to time on the open market at prevailing market prices or in negotiated transactions off the market.

08:11 EDT Tyme Technologies announces initiation of HopES Phase 2 trial - Tyme Technologies announced the initiation of the HopES trial conducted in partnership with The Joseph Ahmed Foundation to better understand and help manage high-risk sarcomas which are rare cancers with high unmet medical need. The HopES trial is a prospective open-label Phase 2 trial evaluating the efficacy and safety of SM-88 in two cohorts of patients. Up to 24 evaluable patients will be enrolled. The first cohort will evaluate oral SM-88 as maintenance monotherapy following primary or palliative treatments for Ewing's sarcoma patients with a high risk of relapse or disease progression. The second cohort will determine the clinical benefits of SM-88 as salvage monotherapy for patients with clinically advanced sarcomas. The Joseph Ahmed Foundation is providing funding and patient support for this investigator-initiated HopES Phase II trial of SM-88 in patients with previously-treated metastatic sarcomas. The primary objectives are to measure overall response, stable disease and progression free survival. Secondary objectives include duration of response, overall survival, clinical benefit rate using response evaluation criteria in solid tumors and incidence of treatment-emergent adverse events.

08:07 EDT Trovagene announces research collaboration with Nektar - Trovagene (TROV) announced that Trovagene and Nektar (NKTR) have entered into a research collaboration to explore the combination of Trovagene's PLK1 inhibitor, onvansertib, and Nektar's topoisomerase I inhibitor, ONZEALD, for the treatment of metastatic colorectal cancer. Under the collaboration, the two companies will evaluate the antitumor activity and tolerability of the combination of onvansertib and ONZEALD in two (HT29 - BRAF mutant and HCT-116 - KRAS mutant) preclinical tumor models of colorectal cancer.

08:06 EDT Nektar launches Inheris Biopharma.to develop investigational opioid molecule - Nektar formed Inheris Biopharma, a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will be responsible for launch preparation and commercialization for NKTR-181, a novel, first-in-class, investigational opioid molecule. NKTR-181 is currently under review with the FDA, with a Prescription Drug User Fee Act target action date of August 29. Inheris will also lead development of several Nektar preclinical CNS assets. Inheris has appointed Jay Galeota as President & CEO, Joe Stauffer as Chief Medical Officer and George Shiebler as Senior VP & General Counsel. The new company will be headquartered in northern New Jersey. Jay Galeota has had a 28-year tenure at Merck, where he held several leadership roles including Chief Strategy & Business Development Officer and President of Emerging Businesses.

08:04 EDT Amira Nature Foods announces $9M of contracts - Amira Nature Foods announced that it entered into contracts, which consist of approximately $9M in revenue, to supply rice and institutional products to new customers in the Europe, Middle East, and Africa and Asia regions. The company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020.

08:03 EDT Pointer Telocation CEO sees double-digit growth in 2019 revenues - Pointer CEO David Mahlab stated, "For the remainder of 2019, we continue to expect double-digit growth in our overall business. We expect to see significant revenues in the second quarter from product sales in North America, fulfilling our largest product order ever, as announced earlier this year, and stable growth in our service business supported by the recently announced service orders in Brazil. These should accelerate growth on our top and bottom lines in the second half of the year."

07:55 EDT BioSig Technologies allowed 33 patent claims covering Pure EP System - BioSig Technologies announced that the U.S. Patent Office allowed 33 patent claims covering its Pure EP System. The patent application number 16/271,462 was filed on May 9, 2018 and subject to an accelerated track one patent application filed on February 8. The patent has not yet been published. The allowed claims address a system for visualizing signals such as low amplitude cardiac signals during an ablation procedure in the presence of noise. Specifically, the allowed claims address a novel way to solve a key technological need of how to synchronize the processing and display of multiple signals in near real-time.

07:31 EDT S&W Seed trading resumes

07:12 EDT Best Buy up 2.4% after reporting better than expected Q1 results

07:11 EDT Village Farms begins facility conversion for hemp cultiviation and extraction - Village Farms has begun conversion of half of its 1.3 million square foot, ultra-high-tech Permian Basin greenhouse, which utilizes the company's proprietary Gates technology, for both cultivation of high-cannabidiol, or CBD, hemp and CBD extraction. This is driven by the expectation that following the House of Representatives concurring with the Senate amendments, House Bill 1325 will become law in Texas, subject to the June 16, 2019 deadline for the Governor to veto bills. As a result of this legislative change, The Texas Hemp Legislation will require licenses for both the cultivation and processing of hemp. Village Farms plans to apply for the requisite licenses as soon as it is permitted to do under the new legislation. No time frame has yet been provided by the State of Texas for the licensing process. Village Farms has commenced conversion of the approximately 635,000 square feet of growing area at the Permian Basin facility for hemp production, with the tomato crop having already been removed and the construction team on site. The company could, with existing systems and at this time of year, immediately begin cultivating hemp if it was licensed to do so. Village Farms expects the Permian Basin facility to be ready for year-round production in Q3, with extraction operations also to be added in the existing facility in 2019. CBD is forecast to generate sales in the U.S. of more than $16B by 2025.

07:07 EDT Alliance Data signs multi-year agreement with Carter's - Alliance Data Systems (ADS) announced its Columbus, Ohio-based card services business has signed a new agreement to provide private label credit card services for the U.S. Retail segment of Carter's (CRI), North America's largest branded marketer of apparel exclusively for babies and young children. Alliance Data will create a data-driven credit card program for Carter's that will integrate with the company's current rewards program, Rewarding Moments, to provide further value to Carter's customers shopping at company-operated stores and websites in the U.S.

07:05 EDT Ansys and Analytical Graphics launch technology partnership - Ansys is integrating mission analysis into the engineering design process thanks to a newly formed technology partnership with Analytical Graphics, or AGI, a provider of systems and mission simulation. Through the partnership, AGI expects to enable satellite, aerospace and defense customers to create more precise and reliable modeling and mission simulations with greater accuracy for complex scenarios, including aircraft missions through contested airspace and satellites orbiting the Earth.

07:02 EDT Carter's announces launch of new branded credit card program - Carter's (CRI) announced the launch of a new branded credit card program in its retail stores and eCommerce channels, providing its customers even more ways to earn rewards when shopping for their favorite children's apparel brands and related products. The new Carter's credit card is expected to be available in select markets this month and in all U.S. stores and websites later this summer. The Carter's credit card is an enhancement of the Company's existing Rewarding Moments(R) loyalty program, which has over 12M active members. Carter's designed its credit card program to provide new rewards for its customers including free shipping on every order, double points and exclusive cardholder-only events. Carter's partnered with Alliance Data (ADS) to bring its credit card to market.

06:58 EDT Tesla falls 4%, or $7.38, to $185.35 in premarket trading

06:55 EDT BJ's Wholesale CEO says 'continue to see momentum across our business' - "We are pleased with our solid start to the year," said Christopher Baldwin, Chairman and CEO, BJ's Wholesale Club. "We delivered merchandise comparable sales of 1.9%, improved margins and continued to grow earnings by executing against our strategic priorities. Looking forward, we continue to see momentum across our business and are encouraged by the opportunities ahead of us, as we continue to transform BJ's Wholesale Club." "In addition, Robert Steele has been appointed to serve as BJ's Lead Independent Director," said Baldwin. "His extensive experience and knowledge of our industry and business will be invaluable to our company."

06:49 EDT Medtronic CEO says expects revenue growth to 'accelerate' over course of FY20 - "The company continues to make significant progress on our pipeline," said CEO Ishrak. "We expect our revenue growth to accelerate over the course of fiscal year 2020 and into fiscal year 2021, driven by the anniversary of recent headwinds, combined with a series of major product launches over the next 12 months."

06:46 EDT Advanced Drainage declares special cash dividend of $1.00 per share - Advanced Drainage Systems has approved a special cash dividend of $1.00 per share. The special dividend of $1.00 per share will be paid on June 14 to shareholders of record at the close of business on June 3. The aggregate payment will be approximately $75M, funded through existing cash and additional borrowings. The special dividend on loan encumbered ESOP preferred shares will be used by the ESOP to repay a portion of the outstanding ESOP loan balance owed to the company, triggering a one-time non-cash, non-tax-deductible ESOP compensation charge that the company expects to realize in 1Q20.

06:44 EDT L Brands sees Q2 SSS about flat - In slides and commentary being presented ahead of its earnings conference call, sees FY19 SSS up low single digits. Sees free cash flow for the year of about $700M. Sees Q2 gross margin down from 35.5% last year, sees FY19 gross margin down from 37.7% last year. The company says it remains "highly focused" on improving performance in the Victoria's Secret and PINK businesses. With respect to tariffs, versus its previous guidance, the company says its forecast does include the additional impact from the recent increase to the List 3 of tariffs on goods imported from China. It added: "Our largest country of supply is the U.S. where the majority of Bath & Body Works and Victoria's Secret Beauty products are FINAL 6 produced. Our lingerie and apparel merchandise is principally produced in Asia, but across a well-diversified group of countries, with no one country having a majority of production. China currently represents a little under 20% of our total production, and we have taken and will continue to take action to mitigate our exposure to China."

06:35 EDT Toronto-Dominion to repurchase 20M shares - TD Bank Group announced that, subject to the approval of the Office of the Superintendent of Financial Institutions Canada and the Toronto Stock Exchange, it intends to launch a normal course issuer bid to repurchase for cancellation up to 20M of its common shares, representing approximately 1.1% of the 1,829,097,656 common shares issued and outstanding as at April 30. TD will file a notice of intention with the TSX in this regard.

06:23 EDT Thermo Fisher raises medium term organic growth outlook to 5%-7% from 4%-6% - As part of its Analyst Day presentation yesterday, Thermo Fisher boosted its 2020-2022 organic growth forecast to 5%-7% from 4%-6%. Sees margin expansion of 40-50 bps from organic growth generated. Sees free cash flow grow equal to the rate of adjusted EPS, which is expected to grow 13%-15%. The company says its "long-term outlook is very attractive" as it is "uniquely positioned to capitalize on opportunities in Pharma & Biotech and China." Reference Link

06:09 EDT American Honda recalls approx. 19,000 Acura, Honda vehicles in the U.S. - American Honda (AMC) will voluntarily recall approximately 19,000 Acura and Honda vehicles in the United States to inspect and, if needed, replace the passenger front airbag module assembly, for free. This recall follows a September 2017 recall and subsequent recall expansions in 2017 and 2018 as Honda's investigation into potential dealer technician errors continued.While performing recall replacements of Takata (TKTDY) passenger airbag inflators before May 2018, dealer technicians at several U.S. dealers may have installed replacement inflators incorrectly in these vehicles. If an airbag with an incorrectly-installed inflator deploys in a crash, the airbag may not inflate properly, increasing the risk of injury to passengers. No improper deployments or injuries have been reported related to this issue.

06:06 EDT Nestle, Fonterra to review strategic options for DPA Brazil joint venture - Fonterra and Nestle announced that they agreed to review strategic options for the future ownership of their Dairy Partners Americas Brazil joint venture, including a potential sale of their respective stakes. Fonterra holds a 51% stake and Nestle 49%. In 2018, DPA reported sales of BRL 1 billion. It operates two plants and employs 1,400 people. Nestle, Chamyto, Ninho, Chandelle, Chambinho, Neston and Molico are among the well-known brands marketed by DPA in Brazil. Fonterra and Nestle created DPA in 2003 as a joint venture to manufacture and commercialize dairy products throughout Latin America. In 2014, the joint venture refocused its activities on Brazil and the commercialization of chilled dairy. With this review, Fonterra and Nestle intend to ensure the long-term growth and success of the business. The review is expected to be completed by the end of 2019.

06:05 EDT McEwen Mining initiates commercial production at Gold Bar Mine, Nevada - McEwen Mining declared that commercial production has been achieved today at the Gold Bar Mine, Nevada, as planned. Jack Henris, General Manager of Nevada, has recently joined McEwen to drive operational improvement. Gold recoveries from the heap leach are tracking well compared to the Feasibility Study design criteria. Production is steadily increasing since first gold pour on February 16th, as more ore is placed on the heap leach pad. 2019 production guidance is 50,000 gold ounces at an AISC of $975 per oz. The mine has operated at 125% of our planned 7,200 tons per day production rate on several days during the past month.

05:31 EDT Microsoft announces new new wind energy agreement in the Netherlands - Microsoft announced a new wind energy agreement in the Netherlands. "Microsoft will purchase 90 MW from the massive 731.5 MW offshore wind project, Borssele III/IV, from Dutch sustainable energy company and wind farm developer Eneco." Eneco will provide Microsoft's datacenters with green power for 15 years starting in 2022.